We are live on ! Find out more
ETON icon

Eton Pharmaceutcials

45 hedge funds and large institutions have $28.7M invested in Eton Pharmaceutcials in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,075% more call options, than puts

Call options by funds: $167K | Put options by funds: $4K

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

4.07% more ownership

Funds ownership: 29.87%33.94% (+4.1%)

2% more funds holding

Funds holding: 4445 (+1)

0% less capital invested

Capital invested by funds: $28.8M → $28.7M (-$91.4K)

63% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 16

Holders
45
Holders Change
+1
Holders Change %
+2.27%
% of All Funds
0.65%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
6
Reduced
16
Closed
6
Calls
$167K
Puts
$4K
Net Calls
+$163K
Net Calls Change
-$108K
Name Holding Trade Value Shares
Change
Change in
Stake
OM
1
Opaleye Management
Massachusetts
$7.88M -$178K -50,781 -2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$3.38M
NCM
3
Nantahala Capital Management
Connecticut
$3.1M +$3.29M +940,733 New
WIM
4
Westside Investment Management
California
$1.93M +$40K +11,440 +2%
AI
5
Acuitas Investments
Washington
$1.91M
NPT
6
National Philanthropic Trust
Pennsylvania
$1.62M
PCMI
7
Paradigm Capital Management Inc
New York
$987K
BlackRock
8
BlackRock
New York
$929K -$1.97K -563 -0.2%
BCM
9
Bridgeway Capital Management
Texas
$834K
PHP
10
Parkman Healthcare Partners
Connecticut
$833K +$189K +54,029 +27%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$791K +$21.6K +6,164 +3%
AC
12
Aristides Capital
Kentucky
$658K +$700K +200,000 New
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$442K -$227K -64,931 -33%
TSW
14
Thompson Siegel & Walmsley
Virginia
$420K +$447K +127,724 New
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$395K -$125K -35,812 -23%
SCM
16
Stonepine Capital Management
Oregon
$362K +$385K +110,000 New
Renaissance Technologies
17
Renaissance Technologies
New York
$350K +$145K +41,469 +64%
State Street
18
State Street
Massachusetts
$268K
Bank of New York Mellon
19
Bank of New York Mellon
New York
$245K
Northern Trust
20
Northern Trust
Illinois
$197K -$4.48K -1,281 -2%
Goldman Sachs
21
Goldman Sachs
New York
$189K -$215K -61,352 -52%
SSA
22
Schonfeld Strategic Advisors
New York
$168K -$161K -45,952 -47%
Squarepoint
23
Squarepoint
New York
$136K -$27.4K -7,838 -16%
Connor, Clark & Lunn Investment Management (CC&L)
24
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$115K -$15.6K -4,450 -11%
William Blair & Company
25
William Blair & Company
Illinois
$114K -$8.67K -2,479 -7%

ETON Hedge Fund Activity: Q2 2024 in Review

45 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Eton Pharmaceutcials (ETON) for Q2 2024, worth a combined $28.7M — down 0.32% from $28.8M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ETON positions and 6 closed out — a net gain of 1 holder — while 6 added to existing stakes and 16 trimmed.

The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $3.29M. The largest seller was Susquehanna International Group, cutting an estimated $227K.

  • 45 institutional investors held Eton Pharmaceutcials (ETON) as of Q2 2024, up from 44 in Q1 2024.
  • Funds reported $28.7M of Eton Pharmaceutcials stock for Q2 2024, down 0.32% quarter-over-quarter.
  • 7 funds opened new Eton Pharmaceutcials positions in Q2 2024 and 6 closed out, a net change of +1 holder.
  • The largest Eton Pharmaceutcials buyer in Q2 2024 was Nantahala Capital Management, an estimated $3.29M added.
  • The largest Eton Pharmaceutcials seller in Q2 2024 was Susquehanna International Group, an estimated $227K sold.

Based on aggregated 13F filings for Q2 2024.